CIK 0001649989 · Non-accelerated filer<br>Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 383982704
- Phone
- 6096193990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-03-29 | Auffarth Gerd Director | Grant or award · Stock Option (Right to Buy) | +41,065 | 41,065 | ||
| 2023-03-29 | Gangolli Julian S Director | Grant or award · Stock Option (Right to Buy) | +41,065 | 41,065 | ||
| 2023-03-29 | Sukhtian Faisal Ghiath Director | Grant or award · Stock Option (Right to Buy) | +41,065 | 41,065 | ||
| 2023-03-29 | THURMAN RANDY H Director | Grant or award · Stock Option (Right to Buy) | +41,065 | 41,065 | ||
| 2023-03-29 | HILZINGER KURT J Director | Grant or award · Stock Option (Right to Buy) | +41,065 | 41,065 | ||
| 2023-01-20 | Evanson Jeff Chief Commercial Officer | Sale | −267,000 | $1.11 | $296K | 745,975 |
| 2023-01-19 | Evanson Jeff Chief Commercial Officer | Sale | −103,255 | $1.22 | $126K | 1,012,975 |
| 2023-01-18 | Evanson Jeff Chief Commercial Officer | Sale | −33,738 | $1.25 | $42K | 1,116,230 |
| 2023-01-17 | Evanson Jeff Chief Commercial Officer | Sale | −27,162 | $1.31 | $36K | 1,149,968 |
| 2022-12-28 | Sukhtian Ghiath M. Director | Grant or award | +14,230,418 | $0.88 | $12.5M | 70,047,204 |
| 2022-10-07 | Sukhtian Faisal Ghiath Director | Purchase | +30,000 | $1.29 | $39K | 68,000 |
| 2022-10-07 | Haddadin Yezan Munther Director | Purchase | +3,600 | $1.27 | $5K | 63,343 |
| 2022-10-06 | Haddadin Yezan Munther Director | Purchase | +29,743 | $1.29 | $38K | 59,743 |
| 2022-10-05 | Haddadin Yezan Munther Director | Grant or award · Stock Option (Right to Buy) | +71,998 | 71,998 | ||
| 2022-10-05 | HILZINGER KURT J Director | Grant or award · Stock Option (Right to Buy) | +57,598 | 57,598 | ||
| 2022-10-05 | Gangolli Julian S Director | Grant or award · Stock Option (Right to Buy) | +74,398 | 74,398 | ||
| 2022-10-05 | Haller Julia A Director | Grant or award · Stock Option (Right to Buy) | +42,239 | 42,239 | ||
| 2022-10-05 | Auffarth Gerd Director | Grant or award · Stock Option (Right to Buy) | +42,239 | 42,239 | ||
| 2022-10-05 | Sukhtian Faisal Ghiath Director | Grant or award · Stock Option (Right to Buy) | +74,878 | 74,878 | ||
| 2022-10-05 | Huang Andong Director | Grant or award · Stock Option (Right to Buy) | +38,399 | 38,399 |
Page 6 of 8 · 142 trades